Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hyperpolarization-activated cyclic nucleotide-gated ion channel 4 (HCN4)
- Target
- HCN4
- Molecular classification
- Ion channel, Voltage-gated channel, Cyclic nucleotide-gated channel, Integral membrane protein
01
Overview
HCN4 is a hyperpolarization-activated cyclic nucleotide-gated cation channel responsible for the pacemaker ("funny," If) current in cardiac sino-atrial node cells, essential for spontaneous diastolic depolarization and heartbeat generation. It is permeable to both sodium and potassium ions, activated by membrane hyperpolarization, and modulated by intracellular cyclic nucleotides (especially cAMP). HCN4 is most highly expressed in heart tissue, but also found in the nervous system and embryonic cells. Mutations in HCN4 are associated with various cardiac arrhythmias and developmental disorders. HCN4 is the therapeutic target for ivabradine, a drug used to lower heart rate in angina and heart failure patients. Selectivity and safety remain key challenges in clinical applications due to structural similarity among HCN channel subtypes and broad tissue distribution.
- Other names
- HCN4Hyperpolarization-activated cyclic nucleotide-gated channel 4Hyperpolarization-activated cation channel 4Pacemaker channel 4"Funny" channel 4If channel
02
Mechanism of action
Channel inhibition (e.g., ivabradine binds to the HCN channel pore and reduces the funny current, If, leading to reduced heart rate)
03
Biological functions
Cardiac rhythm generation (pacemaker activity)Control of membrane excitabilityRegulation of heart rate (diastolic depolarization in sino-atrial node)Embryonic left-right patterning and organ developmentSignal transduction
04
Disease associations
Cardiovascular disease (arrhythmias such as sick sinus syndrome, bradycardia, left ventricular noncompaction, Brugada syndrome)Developmental defects (heterotaxia, aberrant cardiac patterning)Other (potential neurological roles due to expression in CNS)
05
Safety considerations
Off-target effects from non-selective channel blockers (ivabradine inhibits multiple HCN isoforms, not just HCN4)Bradycardia, syncope, dizziness due to excessive inhibitionArrhythmia risk with loss or gain of function mutations
06
Interacting drugs
Ivabradine
07
Biomarkers
HCN4 mutations for cardiac arrhythmia risk and patient stratification (e.g., sick sinus syndrome, bradycardia)Expression level in sino-atrial node tissue may predict responsiveness to funny current inhibitors
Beyond the preview
Go deeper on Hyperpolarization-activated cyclic nucleotide-gated ion channel 4 (HCN4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hyperpolarization-activated cyclic nucleotide-gated ion channel 4 (HCN4).